Sign up
Pharma Capital

CytoDyn files for Orphan Drug designation to treat triple-negative breast cancer

CytoDyn Inc (OTCQB:CYDY) CEO Dr. Nader Pourhassan and Chief Medical Officer Dr. Richard Pestell tell Proactive Investors the biotech was able to reduce the incidence of human breast cancer metastasis in a mouse model for cancer with flagship drug leronlimab by more than 98%.

The biotech has filed for Orphan Drug designation to treat triple-negative breast cancer. It also announced plans earlier this week to expand pre-clinical animal studies into eight cancer indications.

 

View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.